The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome: Carbamazepine and oxcarbazepine in alcohol withdrawal syndrome
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The goal of this review is to evaluate the efficacy and safety of carbamazepine and oxcarbazepine in treatment of alcohol withdrawal syndrome (AWS) and determine the role in therapy of both agents. METHODS: Relevant literature was identified through a search of MEDLINE (1966-June 2008), PubMed (1966-June 2008); Cochrane database was performed to identify English-language publications. Search terms included carbamazepine, oxcarbazepine, AWS, alcoholism, substance syndrome withdrawal. RESULTS: In seven studies, including 612 patients, carbamazepine demonstrated significant reduction in alcohol withdrawal scores. However, in comparative trials with a benzodiazepine agent, carbamazepine's ability to prevent alcohol withdrawal seizures (OR = 0.93; 95% CI = 0.06-14.97, P = NS) and delirium tremens (DTs; OR = 1.25; 95% CI = 0.28-5.64, P = NS) was uncertain as a result of insufficient patient enrollment. In three trials, carbamazepine failed to reduce alcohol withdrawal symptoms possibly as a result of delayed administration, inadequate dosage or inadequate sample size. At daily doses of 800 mg either fixed or tapered over 5-9 days, carbamazepine was well tolerated, and safely administered when blood alcohol concentration dropped below 0.15%. The role of oxcarbazepine in AWS is undefined because of inconsistent findings in two trials. CONCLUSION: Carbamazepine has demonstrated safety, tolerability and efficacy in treatment of moderate to severe symptoms of alcohol withdrawal in the inpatient setting. However, trials of carbamazepine provide inconclusive evidence for prevention of alcohol withdrawal seizures and DTs in comparison with benzodiazepines. Benzodiazepines remain the primary treatment of moderate to severe AWS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid
Hillbom, M., Tokola, R., Kuusela, V., Kärkkäinen, P., Källi-Lemma, L., Pilke, A., & Kaste, M. (1989) · Alcohol · doi:10.1016/0741-8329(89)90022-0 · Cited by 81 · cited 1×
“studied the efficacy and tolerability of carbamazepine, sodium valproate and placebo in 138 patients admitted for inpatient detoxification (22).”
Background
Cited by
Recognition and Management of Withdrawal Delirium (Delirium Tremens)
Schuckit, M. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407298 · Cited by 374
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Guidelines for the understanding and management of pain in chronic pancreatitis
Drewes, A. M., Bouwense, S. A. W., Campbell, C. M., Ceyhan, G. O., Delhaye, M., Demir, I. E., Garg, P. K., van Goor, H., Halloran, C., Isaji, S., et al. (2017) · Pancreatology · doi:10.1016/j.pan.2017.07.006 · Cited by 321
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000668 · Cited by 185
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
Metadata
- Authors
- Barrons, R., & Roberts, N.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2009-07-07
- Volume
- 35
- Issue
- 2
- Pages
- 153-167
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W1577772485
- Cited by
- 70
- References
- 2
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome: Carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. https://app.cochat.ai/papers/10.1111/j.1365-2710.2009.01098.x
- The paper
- Barrons, R., & Roberts, N. (2010). The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome: Carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/j.1365-2710.2009.01098.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.